RLAY240920C7500
- 0.55
- +0.40+266.67%
Relay Therapeutics Newsroom
Relay Therapeutics: A Buy Rating on Robust RLY-2608 Performance and Strategic Trial Design
A Quick Look at Today's Ratings for Relay Therapeutics(RLAY.US), With a Forecast Between $17 to $28
On Sep 17, major Wall Street analysts update their ratings for $Relay Therapeutics(RLAY.US)$, with price targets ranging from $17 to $28.Barclays analyst Peter Lawson maintains with a buy rating,
Strength Seen in Relay Therapeutics (RLAY): Can Its 6.7% Jump Turn Into More Strength?
Market Outperform: Relay Therapeutics Leads With Promising PI3K Inhibitor in Competitive Oncology Space
Relay Therapeutics Price Target Maintained With a $28.00/Share by Stifel
Stifel Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $28
Stifel analyst Bradley Canino maintains $Relay Therapeutics(RLAY.US)$ with a buy rating, and maintains the target price at $28.According to TipRanks data, the analyst has a success rate of 47.1% and
Relay up 5% as Street Applauds Breast Cancer Candidate Data
Relay Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Relay Therapeutics Analyst Ratings
H.C. Wainwright Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $19
H.C. Wainwright analyst Robert Burns maintains $Relay Therapeutics(RLAY.US)$ with a buy rating, and adjusts the target price from $18 to $19.According to TipRanks data, the analyst has a success
Buy Rating Affirmed for Relay Therapeutics Amid Promising Clinical Outcomes and Strategic Market Positioning
Express News | Relay Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $19 From $18
Barclays Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $17
Barclays analyst Peter Lawson maintains $Relay Therapeutics(RLAY.US)$ with a buy rating, and maintains the target price at $17.According to TipRanks data, the analyst has a success rate of 45.0% and
Barclays Gives a Buy Rating to Relay Therapeutics (RLAY)
Relay Therapeutics' RLY-2608 Shows Superior Efficacy in Breast Cancer Trial, Merits Buy Rating
Relay Therapeutics Down Over 17%, On Track for Largest Percent Decrease Since April 2023 -- Data Talk
Why Relay Therapeutics (RLAY) Stock Is Down 17% Today
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
Direct impact of changes | Clinical medical company Relay Therapeutics fell more than 21%, and the company announced a second public offering of common shares
The company announced after the market yesterday that it will publicly issue 28,571,429 shares of common stock at a price of $7 per share.
Sector Update: Health Care Stocks Narrowly Mixed Premarket Wednesday